Ciutat Sanitaria i Universitaria de la Vall d'Hebron

Barcelona 08035

0 studies enrolling now · 10 studies all time

What they study most

Acute Myocardial Infarction, Acute Non-cardioembolic Ischemic Stroke, Carcinoma, Non-Small-Cell Lung, Diabetic Retinopathy, Heart Failure, High-risk Transient Ischemic Attack, Lymphoma, Non-Hodgkin, Prevention of Ischemic Stroke, Solid Tumors Harboring NTRK Fusion, Urothelial Carcinoma

Studies at this site

• A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke — Completed
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
• A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children — Running, not enrolling
• Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma — Completed
• Non-proliferative Diabetic Retinopathy Treated With Runcaciguat — Completed
• Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) — Stopped early
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer — Completed
• Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases — Stopped early
• Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain. — Completed
• Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack — Completed